Free Delivery Over $100
|
|
|||
|
||||
OverviewFull Product DetailsAuthor: Jennifer Isaacs (Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, SC, USA) , Luke Whitesell (Whitehead Institute for Biomedical Research, Cambridge, USA)Publisher: Elsevier Science Publishing Co Inc Imprint: Academic Press Inc Volume: 129 Dimensions: Width: 15.20cm , Height: 2.00cm , Length: 22.90cm Weight: 0.630kg ISBN: 9780128022900ISBN 10: 0128022906 Pages: 288 Publication Date: 25 February 2016 Audience: Professional and scholarly , Professional & Vocational Format: Hardback Publisher's Status: Active Availability: Manufactured on demand  We will order this item for you from a manufactured on demand supplier. Table of Contents1. Unusual Suspects in the Twilight Zone between the Hsp90 Interactome and Carcinogenesis Evangelia Vartholomaiou, Pablo C. Echeverría and Didier Picard 2. Impact of Post-translational Modifications on the Anticancer Activity of Hsp90 Inhibitors Mark R. Woodford, Diana Dunn, Jonelle B. Miller,Sami Jamal, Len Neckers and Mehdi Mollapour 3. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects Gaurav Garg, Anuj Khandelwal and Brian S. J. Blagg 4. HSP90 in Cancer: Transcriptional Roles in the Nucleus S. K. Calderwood and L. Neckers 5. Hsp90 as a ‘Chaperone’ of the Epigenome: Insights and Opportunities for Cancer Therapy Jennifer S. Isaacs 6. Emerging Roles of Extracellular Hsp90 in Cancer Daniel Senh Wong and Daniel G. Jay 7. GRP94/gp96 in Cancer: Biology, Structure, Immunology and Drug Development Bill X Wu, Feng Hong, Yongliang Zhang, Ephraim Ansa-Addo and Zihai Li 8. HSP90 and Immune Modulation in Cancer Michael W. Graner 9. Hsp90: A Global Regulator of the Genotype-To-Phenotype Map in Cancers Daniel JaroszReviewsThis classic and essential series presents critical overviews on select aspects of both cancer research and the basic underlying sciences. -AMERICAN SCIENTIST Excellent, highly informative, in-depth reviews.expertly written, up-to-date, and well-referenced. -JOURNAL OF MEDICINAL CHEMISTRY This is a series that has a long tradition of excellence in the field of cancer biology. -DOODY'S PUBLISHING REVIEWS "Praise for the Serial ""This classic and essential series presents critical overviews on select aspects of both cancer research and the basic underlying sciences."" --American Scientist ""Excellent, highly informative, in-depth reviews…expertly written, up-to-date, and well-referenced."" --Journal of Medicinal Chemistry ""This is a series that has a long tradition of excellence in the field of cancer biology."" --Doody’s Publishing Reviews" Author InformationDepartment of Cell and Molecular Pharmacology, Medical University of South Carolina, USA Luke Whitesell is a pediatric oncologist and senior research scientist at the Whitehead Institute. His clinical interests lie in the treatment of children with recurrent, refractory solid tumors. His laboratory efforts focus on the discovery and pre-clinical development of new anticancer drugs that target heat-shock proteins and the cellular heat-shock response. These ancient adaptive mechanisms act genome-wide to restore the normal protein folding environment within cells and enhance the survival of organisms under stress. In contrast to such well-recognized beneficial effects, however, they also enable cells to accommodate the drastic imbalances in signaling and profound alterations in DNA, protein and energy metabolism that occur in cancers. In essence, the malignant lifestyle confers a profound dependence on these “non-oncogenes, strongly supporting the feasibility of targeting them to more effectively treat cancers. Building on these basic insights and the surprising ways in which HSP90 supports the evolution of new abilities in model organisms, a major goal of his current work is to test the idea that inhibiting HSP90 function can delay or prevent the evolution of a very undesirable trait in cancers, namely the acquisition of high level resistance to current chemotherapies. Luke pursued graduate work in pharmacology at Cambridge University prior to completing medical training at Johns Hopkins University and residency at Boston Children’s Hospital. After fellowship training at the National Cancer Institute he joined the University of Arizona where he was Professor of Pediatric Oncology in the College of Medicine prior to taking his current position at the Whitehead Institute in Cambridge, MA. Tab Content 6Author Website:Countries AvailableAll regions |
||||
